Rajkumar, S. Vincent http://orcid.org/0000-0002-5862-1833
Kumar, Shaji http://orcid.org/0000-0001-5392-9284
Lonial, Sagar http://orcid.org/0000-0002-8322-9323
Mateos, Maria Victoria http://orcid.org/0000-0003-2390-1218
Article History
Received: 6 July 2022
Revised: 3 August 2022
Accepted: 10 August 2022
First Online: 5 September 2022
Competing interests
: Dr. Rajkumar reports grants from NIH, outside the submitted work. Dr. Kumar reports consultancy from BMS/Celgene, Takeda, and Janssen), and research funding from BMS/Celgene, Takeda, Novartis, AbbVie, Janssen, and Amgen. Dr. Lonial reports personal fees from Celgene, personal fees from Takeda, personal fees from Amgen, personal fees from BMS, personal fees from GSK, personal fees from Novartis, personal fees from ABBVIE, personal fees from Janssen, other from TG Therapeutics, outside the submitted work. Dr. Mateos reports personal fees from AbbVie; Adaptive Biotechnologies; Amgen; bluebird bio; Celgene, a Bristol-Myers Squibb Company; GSK; Janssen; Oncopeptides; Pfizer; Regeneron; Roche; Sanofi; Seagen; Takeda, outside the submitted work.